{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-017184","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.560119+00:00","generated_at":"2026-06-16T01:04:38.919200+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"REGENXBIO Q1 net loss $66.7M ($1.53/share); cash $473.5M; pipeline advances","bullets":["Cash, equivalents and marketable securities $473.5M as of Mar 31, 2023; runway into 2025.","Revenue $19.1M, down from $22.2M YoY mainly due to lower Zolgensma royalties ($16.1M vs $21.5M).","Net loss $66.7M ($1.53 per share) vs $76.7M ($1.79) YoY; R&D spend up to $58.5M.","Subretinal ABBV-RGX-314 pivotal trials expanded; regulatory submissions expected late 2025 to H1 2026.","RGX-202 Duchenne trial on track for initial data H2 2023; RGX-121 BLA filing planned in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-017184","json":"https://secwatch.observer/filing/0000950170-23-017184.json","markdown":"https://secwatch.observer/filing/0000950170-23-017184.md","text":"https://secwatch.observer/filing/0000950170-23-017184.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000095017023017184/0000950170-23-017184-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000095017023017184/rgnx-20230503.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T01:04:38.919200+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"23b3a10edb8d01b6cdb7097fff6036220b1e4ace","claim":"REGENXBIO Inc. reported financial results for the quarter ended March 31, 2023.","evidence_excerpt":"On May 3, 2023, REGENXBIO Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590877/000095017023017184/0000950170-23-017184-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}